The news of JP Morgan maintaining a Neutral rating on Cardinal Health and raising the price target from $90 to $93 indicates that the analyst sees potential for the stock price to increase. However, the Neutral rating suggests that the analyst does not expect significant outperformance or underperformance in the short term. This news may have a limited impact on the stock price in the short term, as it does not signal a strong buy or sell recommendation.